Frontlight ResearchEarly access
CompletedPhase 3
Efficacy and Safety of ZSP1273 in Adolecent 12-17 Years Old With Influenza A
Key facts
- Who runs it
- Guangdong Raynovent Biotech Co., Ltd
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 3
- People taking part
- 157 people enrolled
- Started
- 8 Nov 2025
- Ended
- 25 Jan 2026
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- ZSP1273
- Placebo
- Record updated
- 9 November 2026
Who can take part
- Age
- 12 years to 17 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Participants and their guardians who are able to understand the study and comply with all study procedures, and willing to provide written informed consent/assent prior to the predose examinations appropriately
- Male or female participants aged ≥ 2 to ≤11 years at the time of signing the informed consent form
- Participants with a diagnosis of influenza virus infection confirmed by all of the following:; Positive rapid antigen test (RAT) for influenza with nasal or throat swabs; The time interval between the onset of symptoms and enrollment is 48 hours or less; Fever ≥ 38ºC (axillary temperature); and at least one following respiratory symptoms associated with influenza virus infection is present
Who cannot take part
- Participants with any medical history in gastrointestinal that interferes with the absorption of drugs;
- Immunodeficiency,including malignant tumor,organ or marrow transplant,human immunodeficiency virus [HIV] infection,or patients receiving immunosuppressant therapy 3 months prior to enrollment;
- Have received any other investigational products within 3 months prior to dosing;
- Participants with concurrent infections requiring antimicrobial therapy;
- Participants with severe influenza virus infection;
- Positive urine pregnancy test;
- Participants who are considered inappropriate for the study by the investigator
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This trial is conducted in China. This is a multi-center, randomized, double-blind, placebo-controlled clinical trial to assess the efficacy and safety of ZSP1273 in the treatment of Acute Uncomplicated influenza A in adolescents.
The 2 groups in the trial
- ZSP1273Treatment being tested
- PlaceboPlacebo, for comparison
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Randomized, Double-blind Phase III Clinical Study of ZSP1273 Tablets Compared With Placebo in Children 12-17 Years Old With Acute Uncomplicated Influenza A
- Record updated
- 9 November 2026